ROS1-rearranged NSCLC is highly sensitive to tyrosine kinase inhibitors (TKI), with superior response rates and clinical outcomes compared to platinum doublet chemotherapy2–4. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.